Form 4 for EDIT Editas Medicine, Inc.
Accepted 2023-03-06 00:00:00 ET · period of report 2023-03-02 · accession 0001415889-23-004315 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-06 | 2023-03-02 | EDIT | ROBERTSON MICHELLE | EVP, CFO | A - Grant | $0.00 | +31.5K | 107.7K | +41% | $0 |
| D | 2023-03-06 | 2023-03-03 | EDIT | ROBERTSON MICHELLE | EVP, CFO | S - Sale | $8.89 | -184 | 107.6K | -0.2% | -$1,636 |
| D | 2023-03-06 | 2023-03-02 | EDIT | ROBERTSON MICHELLE | EVP, CFO | A - Grant | $0.00 | +94.5K | 94.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | A | A | 31,500 | $0.00 | 107,743 | D | — | — | (F1) The common stock received by the Reporting person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027. |
| 2 | Common | Common Stock | 2023-03-03 | S | D | 184 | $8.89 | 107,559 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2023-03-02 | A | A | 94,500 | $0.00 | 94,500 | D | $8.72 · — to 2033-03-01 | 94,500 Common Stock | (F3) This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027. |